Improvements in hepatitis B virus (HBV) treatment have been modest. Investigational anti-HBV agents are considered based on pediatric pathophysiology, including capsid assembly modifiers, antigen secretion inhibitors, silencing RNAs, and immune modulators. Recommendations for screening and treatment of hepatitis B in children with risk factors or comorbidities have also been established.